Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SAPOZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AbA_D265C_LALA_H435A-AM2
|
|||||
| Synonyms |
AbA_D265C_LALA_H435A-AM2
Click to Show/Hide
|
|||||
| Organization |
Vor Biopharma Inec.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2.2
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Receptor-type tyrosine-protein phosphatase C (PTPRC)
|
Antigen Info | ||||
| Payload Name |
US12209180B2 AM2
|
Payload Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 143 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
|
[1] |
| Maximum Observed Concentration (Cmax) | 22.9 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
|
[1] |
| Time to Maximum Concentration (Tmax) | 0.083 | hr |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 143 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
|
[1] |
| Volume of Distribution (Vd) | 76.8 | mL/kg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 143 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 143 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
|
[1] |
| Elimination Half-Life (t1/2) | 14.4 | hr |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
|
[1] |
| Clearance (CL) | 8.2 | mL/hr/kg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
|
[1] |
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 280 pM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro BM HSC killing assay: ADCs conjugated to AM2
|
||||
| In Vitro Model | Bone marrow hematopoietic stem cells | BM HSC cells (CD34+CD90+) | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.0005 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro PBMC killing assays: ADCs conjugated to AM2
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.0008 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro PBMC killing assays: ADCs conjugated to AM2
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.0173 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
in vitro PBMC killing assays: ADCs conjugated to AM1, PBD, or IGN
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.033 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell killing assays: ADCs conjugated to AM1, AM3, or PBD
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.12 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.16 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell killing assays: ADCs conjugated to AM1, AM2, or PBD
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.42 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.538 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
in vitro PBMC killing assays: ADCs conjugated to AM1, PBD, or IGN
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.6071 nM | Positive CD45 expression (CD45+++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | Adult acute myeloid leukemia | SKNO-1 cells | CVCL_2196 | ||